MS
Therapeutic Areas
Kissei Pharmaceutical Pipeline
| Drug | Indication | Phase |
|---|---|---|
| KRP-107 (Pexidartinib) | Tenosynovial Giant Cell Tumor (TGCT) | Marketed |
| KRP-117 (Evocalcet) | Secondary Hyperparathyroidism in CKD on dialysis | Marketed |
| KRP-203 (Finerenone) | Diabetic Kidney Disease / Chronic Kidney Disease in T2D | Marketed |
| KRP-205 | Focal Segmental Glomerulosclerosis (FSGS) | Phase II |
| KRP-209 | Idiopathic Pulmonary Fibrosis (IPF) | Phase II |
| KRP-210 | Ulcerative Colitis | Phase II |
| KRP-211 | Prostate Cancer | Phase I/II |
| KRP-212 | Castration-Resistant Prostate Cancer (CRPC) | Phase I |
Leadership Team at Kissei Pharmaceutical
KM
Kazuhiko Mori
Director and Senior Managing Executive Officer (R&D)
SO
Shinji Orita
Director and Managing Executive Officer